2023
DOI: 10.1016/j.phrs.2022.106554
|View full text |Cite
|
Sign up to set email alerts
|

Functional metabolomics revealed the dual-activation of cAMP-AMP axis is a novel therapeutic target of pancreatic cancer

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
4
0

Year Published

2024
2024
2025
2025

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 7 publications
(4 citation statements)
references
References 47 publications
0
4
0
Order By: Relevance
“…The heatmaps were drawn via TBtools [30]. The PCoA, correlation heatmaps, and RDA analysis were performed on Omicshare Tools (https://www.omicshare.com/tools/, accessed on 10 December 2023) [31,32].…”
Section: Discussionmentioning
confidence: 99%
“…The heatmaps were drawn via TBtools [30]. The PCoA, correlation heatmaps, and RDA analysis were performed on Omicshare Tools (https://www.omicshare.com/tools/, accessed on 10 December 2023) [31,32].…”
Section: Discussionmentioning
confidence: 99%
“…Finally, it was verified that the accumulation of AMP and cAMP induced by gemcitabine can, respectively, activate the downstream kinases AMP-activated protein kinase and protein kinase A, leading to tumor growth inhibition through the overexpression of growth arrest and DNA damage-inducible protein 45A. The dual activation of the AMP-cAMP axis represents a potential new target for PC treatment [ 63 ].…”
Section: Classical Multi-omics Integration Methodsmentioning
confidence: 99%
“… 15 Besides their role as biomarkers, small‐molecule metabolites can directly interact with drugs to coordinate therapeutic strategies or bind with proteins to regulate various physiological functions, alter disease‐related signaling pathways, and affect disease progression. 16 , 17 , 18 , 19 Previous research has also underscored the potential of metabolites to regulate neuroinflammation and the post‐injury microenvironment following SCI. According to the research by Zeng et al., there is a disruption in purine metabolism after SCI, with significant changes in multiple genes and metabolites, which may participate in processes such as inflammation, apoptosis, and axonal regeneration following SCI.…”
Section: Introductionmentioning
confidence: 99%
“…In early breast cancer, metabolites like glutamine, tyrosine, proline, histidine, alanine, and citrate have been associated with proliferating tumor cells 15 . Besides their role as biomarkers, small‐molecule metabolites can directly interact with drugs to coordinate therapeutic strategies or bind with proteins to regulate various physiological functions, alter disease‐related signaling pathways, and affect disease progression 16–19 . Previous research has also underscored the potential of metabolites to regulate neuroinflammation and the post‐injury microenvironment following SCI.…”
Section: Introductionmentioning
confidence: 99%